Annual ROE
198.42%
-23.65%-10.65%
December 31, 2024
Summary
- As of February 22, 2025, HALO annual return on equity is 198.42%, with the most recent change of -23.65% (-10.65%) on December 31, 2024.
- During the last 3 years, HALO annual ROE has fallen by -33.02% (-14.27%).
- HALO annual ROE is now -33.63% below its all-time high of 298.95%, reached on December 31, 2002.
Performance
HALO ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
138.37%
-18.25%-11.65%
December 31, 2024
Summary
- As of February 22, 2025, HALO quarterly return on equity is 138.37%, with the most recent change of -18.25% (-11.65%) on December 31, 2024.
- Over the past year, HALO quarterly ROE has dropped by -57.27% (-29.27%).
- HALO quarterly ROE is now -97.85% below its all-time high of 6447.16%, reached on December 31, 2002.
Performance
HALO Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
HALO ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -10.7% | -29.3% |
| 3 y3 years | -14.3% | -20.1% |
| 5 y5 years | +567.9% | -20.1% |
HALO ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -14.3% | +80.0% | -43.9% | +47.9% |
| 5 y | 5-year | -14.3% | +567.9% | -51.4% | +416.1% |
| alltime | all time | -33.6% | +110.1% | -97.8% | +100.1% |
Halozyme Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | 198.42%(-10.6%) | 138.37%(-11.7%) |
| Sep 2024 | - | 156.62%(-11.7%) |
| Jun 2024 | - | 177.29%(-19.1%) |
| Mar 2024 | - | 219.05%(+12.0%) |
| Dec 2023 | 222.07%(+101.5%) | 195.64%(+12.9%) |
| Sep 2023 | - | 173.23%(+15.2%) |
| Jun 2023 | - | 150.42%(+46.8%) |
| Mar 2023 | - | 102.50%(+3.2%) |
| Dec 2022 | 110.23%(-52.4%) | 99.36%(+6.2%) |
| Sep 2022 | - | 93.53%(-41.2%) |
| Jun 2022 | - | 158.95%(-32.3%) |
| Mar 2022 | - | 234.78%(-4.7%) |
| Dec 2021 | 231.44%(+117.7%) | 246.45%(-13.4%) |
| Sep 2021 | - | 284.47%(+35.1%) |
| Jun 2021 | - | 210.63%(+24.3%) |
| Mar 2021 | - | 169.44%(+32.7%) |
| Dec 2020 | 106.33%(-350.7%) | 127.70%(+611.8%) |
| Sep 2020 | - | 17.94%(-168.8%) |
| Jun 2020 | - | -26.09%(-40.4%) |
| Mar 2020 | - | -43.78%(+34.0%) |
| Dec 2019 | -42.41%(+20.7%) | -32.66%(+104.9%) |
| Sep 2019 | - | -15.94%(-5.9%) |
| Jun 2019 | - | -16.94%(-15.8%) |
| Mar 2019 | - | -20.13%(-39.0%) |
| Dec 2018 | -35.14%(-149.1%) | -33.00%(-250.3%) |
| Sep 2018 | - | 21.95%(-50.6%) |
| Jun 2018 | - | 44.40%(-29.2%) |
| Mar 2018 | - | 62.70%(-50.6%) |
| Dec 2017 | 71.60%(-103.7%) | 126.99%(-107.9%) |
| Sep 2017 | - | -1600.63%(-249.4%) |
| Jun 2017 | - | 1071.19%(+114.6%) |
| Mar 2017 | - | 499.09%(-136.7%) |
| Dec 2016 | -1958.98%(+2463.4%) | -1358.50%(+289.3%) |
| Sep 2016 | - | -348.93%(+71.7%) |
| Jun 2016 | - | -203.24%(+111.3%) |
| Mar 2016 | - | -96.17%(+21.7%) |
| Dec 2015 | -76.42%(-88.1%) | -79.03%(-24.1%) |
| Sep 2015 | - | -104.11%(+24.1%) |
| Jun 2015 | - | -83.89%(-29.0%) |
| Mar 2015 | - | -118.18%(-36.6%) |
| Dec 2014 | -640.16%(+10.7%) | -186.46%(-39.3%) |
| Sep 2014 | - | -307.15%(-19.9%) |
| Jun 2014 | - | -383.27%(-27.3%) |
| Mar 2014 | - | -526.96%(-13.9%) |
| Dec 2013 | -578.44% | -612.00%(+158.9%) |
| Sep 2013 | - | -236.39%(+50.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2013 | - | -157.03%(+53.5%) |
| Mar 2013 | - | -102.33%(-0.2%) |
| Dec 2012 | -179.24%(+41.7%) | -102.50%(-27.3%) |
| Sep 2012 | - | -141.08%(+38.7%) |
| Jun 2012 | - | -101.75%(+23.0%) |
| Mar 2012 | - | -82.75%(-23.1%) |
| Dec 2011 | -126.52%(-67.6%) | -107.59%(+36.8%) |
| Sep 2011 | - | -78.67%(-67.1%) |
| Jun 2011 | - | -239.44%(-51.7%) |
| Mar 2011 | - | -495.43%(-16.3%) |
| Dec 2010 | -390.69%(-25.4%) | -592.24%(-0.4%) |
| Sep 2010 | - | -594.84%(-23.2%) |
| Jun 2010 | - | -774.05%(+41.5%) |
| Mar 2010 | - | -546.89%(+29.8%) |
| Dec 2009 | -523.80%(+293.7%) | -421.42%(+25.7%) |
| Sep 2009 | - | -335.33%(+31.1%) |
| Jun 2009 | - | -255.78%(+33.2%) |
| Mar 2009 | - | -192.02%(+52.3%) |
| Dec 2008 | -133.03%(+125.1%) | -126.07%(+50.8%) |
| Sep 2008 | - | -83.58%(+28.6%) |
| Jun 2008 | - | -64.98%(+20.9%) |
| Mar 2008 | - | -53.76%(+15.8%) |
| Dec 2007 | -59.11%(-17.3%) | -46.41%(+1.9%) |
| Sep 2007 | - | -45.56%(-7.6%) |
| Jun 2007 | - | -49.29%(-26.0%) |
| Mar 2007 | - | -66.61%(-21.4%) |
| Dec 2006 | -71.46%(-11.1%) | -84.74%(-15.1%) |
| Sep 2006 | - | -99.87%(-8.7%) |
| Jun 2006 | - | -109.40%(-1.3%) |
| Mar 2006 | - | -110.83%(-0.2%) |
| Dec 2005 | -80.38%(-32.8%) | -111.04%(-21.3%) |
| Sep 2005 | - | -141.14%(+2.2%) |
| Jun 2005 | - | -138.08%(+1.5%) |
| Mar 2005 | - | -136.00%(-13.6%) |
| Dec 2004 | -119.64%(-78.9%) | -157.47%(-41.7%) |
| Sep 2004 | - | -269.89%(+39.3%) |
| Jun 2004 | - | -193.79%(-6.5%) |
| Mar 2004 | - | -207.24%(-95.9%) |
| Dec 2003 | -565.81%(-289.3%) | -5097.82%(-195.1%) |
| Sep 2003 | - | 5357.93%(-127.7%) |
| Jun 2003 | - | -19.34 K%(-80.6%) |
| Mar 2003 | - | -99.44 K%(-1642.4%) |
| Dec 2002 | 298.95%(-271.7%) | 6447.16%(<-9900.0%) |
| Sep 2002 | - | -18.73%(+147.4%) |
| Jun 2002 | - | -7.57%(-126.4%) |
| Mar 2002 | - | 28.66% |
| Dec 2001 | -174.12% | - |
FAQ
- What is Halozyme Therapeutics annual return on equity?
- What is the all time high annual ROE for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual ROE year-on-year change?
- What is Halozyme Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly ROE year-on-year change?
What is Halozyme Therapeutics annual return on equity?
The current annual ROE of HALO is 198.42%
What is the all time high annual ROE for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual return on equity is 298.95%
What is Halozyme Therapeutics annual ROE year-on-year change?
Over the past year, HALO annual return on equity has changed by -23.65% (-10.65%)
What is Halozyme Therapeutics quarterly return on equity?
The current quarterly ROE of HALO is 138.37%
What is the all time high quarterly ROE for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly return on equity is 6447.16%
What is Halozyme Therapeutics quarterly ROE year-on-year change?
Over the past year, HALO quarterly return on equity has changed by -57.27% (-29.27%)